PK and Safety of Mitapivat 100 mg vs 2x50 mg Tablets in Healthy Adults

Phase 1, randomised, open-label trial of mitapivat in pyruvate kinase deficiency (PKD) (2 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve of Mitapivat From Time 0 to the Last Quantifiable Concentration, Area Under the Plasma Concentration Versus Time Curve of Mitapivat From Time 0 Extrapolated to Infinity and 6 more. Started Jan 2021; status: completed.